Etzer Darout
Stock Analyst at Guggenheim
(1.90)
# 2,811
Out of 4,810 analysts
109
Total ratings
31.71%
Success rate
-9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.24 | +177.56% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $7.56 | +164.73% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $47.06 | +53.00% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $100.62 | +42.12% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.94 | +55.04% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.27 | +57.48% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $36.06 | +10.93% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $14.82 | +237.38% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $10.01 | +249.65% | 1 | Dec 6, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Market Perform | $55 | $25.66 | +114.38% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $4.16 | +1,414.42% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.93 | +1,300.05% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $70.37 | +90.42% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $9.12 | +272.81% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $19.61 | +144.77% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $109.82 | +9.27% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $30.58 | +24.26% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $2.34 | +1,011.11% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $5.13 | +387.33% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.31 | +281.68% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.29 | +1,456.42% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $42.40 | +114.65% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.01 | +494.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.63 | +469.75% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $68.12 | +20.38% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $3.71 | +412.13% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $236.73 | -28.19% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $5.66 | +1,384.10% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $38.62 | +39.82% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $40.24 | -5.57% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.20 | +4,251.46% | 1 | Mar 28, 2018 |
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.24
Upside: +177.56%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.56
Upside: +164.73%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $47.06
Upside: +53.00%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $100.62
Upside: +42.12%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.94
Upside: +55.04%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.27
Upside: +57.48%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $36.06
Upside: +10.93%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $14.82
Upside: +237.38%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $10.01
Upside: +249.65%
Kymera Therapeutics
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $25.66
Upside: +114.38%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $4.16
Upside: +1,414.42%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.93
Upside: +1,300.05%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $70.37
Upside: +90.42%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $9.12
Upside: +272.81%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $19.61
Upside: +144.77%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $109.82
Upside: +9.27%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $30.58
Upside: +24.26%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $2.34
Upside: +1,011.11%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $5.13
Upside: +387.33%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.31
Upside: +281.68%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.29
Upside: +1,456.42%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $42.40
Upside: +114.65%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.01
Upside: +494.00%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.63
Upside: +469.75%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $68.12
Upside: +20.38%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $3.71
Upside: +412.13%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $236.73
Upside: -28.19%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $5.66
Upside: +1,384.10%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $38.62
Upside: +39.82%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $40.24
Upside: -5.57%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.20
Upside: +4,251.46%